- Trials with a EudraCT protocol (44,341)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,341 result(s) found.
Displaying page 1,765 of 2,218.
EudraCT Number: 2021-002311-64 | Sponsor Protocol Number: SuloPrima | Start Date*: 2021-10-01 | |||||||||||
Sponsor Name:ALFASIGMA CZECH s.r.o. | |||||||||||||
Full Title: Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial | |||||||||||||
Medical condition: Chronic primary venous disease of the lower limbs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002665-30 | Sponsor Protocol Number: RENAISSANCE | Start Date*: 2016-01-11 |
Sponsor Name:Krankenhaus Nordwest gGmbH | ||
Full Title: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric jun... | ||
Medical condition: limited-metastatic adenocarcinoma of the stomach or esophagogastric junction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004536-28 | Sponsor Protocol Number: 1 | Start Date*: 2021-11-15 |
Sponsor Name:Uppsala University, Department of Women's and Children´s Health | ||
Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi... | ||
Medical condition: Most troublesome vulvovaginal atrophy symptom | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003648-55 | Sponsor Protocol Number: EZH-301 | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Epizyme, Inc. | ||||||||||||||||||
Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | ||||||||||||||||||
Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001013-81 | Sponsor Protocol Number: ProBaBle | Start Date*: 2014-10-10 | |||||||||||
Sponsor Name:Centro Hospitalar de São João, EPE | |||||||||||||
Full Title: Treatment of Bladder Pain Syndrome with Onabotulinum toxin A | |||||||||||||
Medical condition: Bladder Pain Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000302-10 | Sponsor Protocol Number: UHKT-COVID19 | Start Date*: 2022-01-24 |
Sponsor Name:Institute of hematology and blood transfusion | ||
Full Title: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system | ||
Medical condition: Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005461-14 | Sponsor Protocol Number: LD-VenEx | Start Date*: 2022-04-20 |
Sponsor Name:Righospitalet | ||
Full Title: The Nordic AML Group – LD-VenEx: PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (INCLUDING EXPLORATORY EVALUATION OF EX VIVO DRUG SENS... | ||
Medical condition: Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001335-31 | Sponsor Protocol Number: virus-specific_CD8_T-cells_001 | Start Date*: 2013-11-08 |
Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta | ||
Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation | ||
Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000876-40 | Sponsor Protocol Number: IJB-REGINA-2020 | Start Date*: 2021-03-09 | ||||||||||||||||
Sponsor Name:Institut Jules Bordet | ||||||||||||||||||
Full Title: A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancer | ||||||||||||||||||
Medical condition: rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002385-31 | Sponsor Protocol Number: 2015/582 | Start Date*: 2017-08-28 | |||||||||||
Sponsor Name:Professor Peter Humaidan, The Fertility Clinic Skive | |||||||||||||
Full Title: A double-blind, placebo-controlled multicenter trial on the effect of clindamycin and a live biotherapeutic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003399-58 | Sponsor Protocol Number: COPTRIN1 | Start Date*: 2017-01-14 | |||||||||||
Sponsor Name:COP:TRIN Region Hovedstaden (Gentofte hospital) | |||||||||||||
Full Title: Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease): Can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa infected patients with chronic pulmonary obstructiv... | |||||||||||||
Medical condition: Respiratory tract infection Bacterial infection with Pseudomonas aeruginosa Chronic obstructive pulmonary disease (COPD) Non-cystic fibrosis bronchiectasis Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003797-51 | Sponsor Protocol Number: D5680C00003 | Start Date*: 2021-07-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects with Painful Osteoarthritis of the Knee | |||||||||||||
Medical condition: Painful osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005802-24 | Sponsor Protocol Number: ADP-0055-002 | Start Date*: 2022-03-21 | |||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||
Full Title: A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers | |||||||||||||
Medical condition: advanced esophageal or esophagogastric junction (EGJ) cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001981-13 | Sponsor Protocol Number: INCB54707204 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | |||||||||||||
Medical condition: Hidradenitis Suppurativa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2024-000141-26 | Sponsor Protocol Number: B7451094 | Start Date*: 2024-06-21 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABROCITINIB 100 MG AND 200 MG TABLETS IN PARTICIPANTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DE... | |||||||||||||
Medical condition: Moderate to severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004045-16 | Sponsor Protocol Number: ET18-272 | Start Date*: 2019-03-14 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo... | ||
Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004980-24 | Sponsor Protocol Number: mRNA-3705-P101 | Start Date*: 2023-08-21 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidem... | ||
Medical condition: Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001728-33 | Sponsor Protocol Number: 2020-001728-33 | Start Date*: 2020-12-14 |
Sponsor Name:Region Skåne | ||
Full Title: Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) | ||
Medical condition: Primary or recurrent non-muscle invasive bladder cancer with intermediate risk of recurrence after transurethral tumour resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001046-17 | Sponsor Protocol Number: SMART-2019 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Uppsala University | |||||||||||||
Full Title: A multicentre, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascu... | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023362-44 | Sponsor Protocol Number: ITAC 2 | Start Date*: 2010-11-11 |
Sponsor Name:Institute of oncology Ljubljana | ||
Full Title: ITAC 2 TRIAL: INTERMITTENT TKI AND CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER | ||
Medical condition: The study population consists of patients aged 18 years and older who have histologicaly or cytologicaly proven locally advanced or metastatic NSCLC with activating mutation of EGFR, chemonaive and... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
